Syntaxin raises $33M for biologics

11/1/2007 | Reuters

GlaxoSmithKline's venture-capital unit SR One co-led a new funding round that raised $33 million for Syntaxin Ltd. The firm is trying to develop experimental biologics for the treatment of pain and nervous, respiratory and metabolic disorders using a protein-based technology that controls the aberrant secretion of hormones linked to diseases.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ